Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 8,301–8,400 of 15,747
Azarias-da-Silva, M., Nioche, P., Soudaramourty, C., Bull-Maurer, A., Tiouajni, M., Kong, D., Zghidi‐Abouzid, O., Picard, M., Mendes‐Frias, A., Cruz, A. S., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg2122 · Cited by 6
Menstrual cycle changes: A cross-sectional study of Saudi females following SARS-CoV-2 infection
Abdel-Moneim, Y. A. S., Alghamdi, H. Y., Alrashed, A. M., Jawhari, A. M., Bukhari, S. M. M., Bukhari, N. M. M., & Abdel-Moneim, A. S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279408 · Cited by 9
Systems biological assessment of human immunity to BNT162b2 mRNA vaccination
Arunachalam, P. S., Scott, M. K. D., Hagan, T., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-438662/v1 · Cited by 11
Matkowska‐Kocjan, A., Owoc‐Lempach, J., Ludwikowska, K. M., Szenborn, F., Moskwa, N., Kurek, K., Kałwak, K., Szenborn, L., & Ussowicz, M. (2023) · Vaccines · doi:10.3390/vaccines11010195 · Cited by 9
“Comparing our experience with studies in adult patients vaccinated with the 30 μg BNT162b2 vaccine, it becomes clear that children tolerate vaccination even better than adults [14,33].”
Zamagni, G., Armocida, B., Abbafati, C., Ronfani, L., & Monasta, L. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.825416 · Cited by 8
Selvaraj, P., Wagner, B. G., Chao, D. L., L’Azou, M., Breugelmans, J. G., Jackson, N., & Chang, S. T. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000053 · Cited by 8
Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over
Kim, S., Ko, M., Heo, Y., Lee, Y.-K., Kwon, Y., Choi, S.-K., & Bahng, E. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.06.077 · Cited by 6
Odainic, A., Spitzer, J., Szlapa, J., Schade, S., Krämer, T. J., Neuberger, J., Bode, C., Steinhagen, F., Schmithausen, R. M., Wilbring, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012231 · Cited by 7
“The general recommended vaccination scheme [17,18] for mRNA-based vaccines from Moderna (Spikevax [19]) or Pfizer–BioNTech (Comirnaty [20]) includes two inoculations with a temporal difference of 4 to 8 weeks and a recommended booster after six months.”
BackgroundVirus-like Particles (VLPs) as Important Tools for Flavivirus Vaccine Development
Castilho, L. R., de Mattos, N. R., Abreu, W. S., & Gutarra, M. L. E. (2022) · Biologics · doi:10.3390/biologics2040018 · Cited by 9
Marra, A. R., Kobayashi, T., Suzuki, H., Alsuhaibani, M., Tofaneto, B. M., Bariani, L. M., Auler, M. D. A., Salinas, J. L., Edmond, M. B., Pinho, J. R. R., et al. (2021) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2021.195 · Cited by 8
“Full-text ar cles assessed for eligibility n =35 19 Ar cles excluded: no comparison between vaccinated and unvaccinated (11); no VE available data (2); preprint paper (2); no outcome described about COVID-19 (1); research protocol (1); survey (1); duplicate study (1) Studies included in qualita ve synthesis n =16”
BackgroundTriazole-linked Nucleic Acids: Synthesis, Therapeutics and Synthetic Biology Applications
Sharma, V. K., Mangla, P., Singh, S. K., & Prasad, A. K. (2023) · Current Organic Synthesis · doi:10.2174/1570179420666230502123950 · Cited by 8
Abbasi, S., Matsui-Masai, M., Yasui, F., Hayashi, A., Tockary, T. A., Akinaga, S., Kohara, M., Kataoka, K., & Uchida, S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.27.530188 · Cited by 9
Schepens, B., van Schie, L., Nerinckx, W., Roose, K., Breedam, W. V., Fijałkowska, D., Devos, S., Weyts, W., Cae, S. D., Vanmarcke, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.08.433449 · Cited by 7
Deb, P., Molla, M. M. A., Saif‐Ur‐Rahman, K., Das, M. C., & Das, D. (2021) · Egyptian Journal of Bronchology · doi:10.1186/s43168-021-00090-x · Cited by 8
Expert Perspectives on COVID-19 Vaccination for People Living with Multiple Sclerosis
Shin, R. K., Rammohan, K. W., & Williams, M. J. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00266-z · Cited by 7
“The first two that we had were Pfizer-BioNTech as a collaboration (NCT04368728) [2], and then there’s a Moderna vaccine (NCT04470427) [3], and both of these vaccines are mRNA vaccines.”
BackgroundAdvancements in SARS-CoV-2 detection: Navigating the molecular landscape and diagnostic technologies
Almulla, N., Soltane, R., Alasiri, A., Allayeh, A. K., Alqadi, T., Alshehri, F., Alrokban, A. H., Zaghlool, S. S., Zayan, A. Z., Abdalla, K. F., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29909 · Cited by 7
“A remarkable degree of sensitivity was specifically noted during the initial three days following the onset of symptoms, as well as in subjects whose viral load was at or above 6 log10 SARS-CoV-2 RNA copies per milliliter [78,79].”
BackgroundMethodInfluentialRetractedSinganayagam, A., Hakki, S., Dunning, J. W., Madon, K. J., Crone, M. A., Koycheva, A., Derqui, N., Barnett, J. L., Whitfield, M. G., Varro, R., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3918287 · Cited by 7
Oshida, S., Akamatsu, Y., Matsumoto, Y., Suzuki, T., Sasaki, T., Kondo, Y., Fujiwara, S., Kashimura, H., Kubo, Y., & Ogasawara, K. (2022) · Surgical Neurology International · doi:10.25259/sni_1144_2021 · Cited by 7
“A previous systematic review[16] and a meta-analysis[21] have characterized the safety profile of the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine (Pfizer, Philadelphia, PA), identifying common reactions in the short-term of mild-tomoderate pain at the injection site, fatigue, and headache.”
BackgroundMethodGalván, V., & Quarleri, J. F. (2021) · GeroScience · doi:10.1007/s11357-021-00501-3 · Cited by 7
DiRago, N. V., Li, M., Tom, T., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3918562 · Cited by 7
Mechanisms of Myocardial Injury in COVID-19
Bularga, A., Chapman, A. R., & Mills, N. L. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvab111 · Cited by 7
The coronavirus disease 2019 (COVID-19) pandemic—Looking back and looking forward
Henderson, D. K., Haessler, S., & Weber, D. J. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.338 · Cited by 8
Tadfor, Y., Nguyen-Hua, N., Bennett, H., Bos, A. J., & Smolinske, S. C. (2022) · Clinical Toxicology · doi:10.1080/15563650.2022.2147272 · Cited by 6
Venous sinus thrombosis after the first dose of Pfizer BioNTech vaccine
Qureshi, M. I. A., Azam, B., Waheed, M. A., et al. (2022) · BMJ Case Reports · doi:10.1136/bcr-2021-247493 · Cited by 7
SARS-CoV-2 humoral immunity in people living with HIV-1
Motsoeneng, B. M., Bhiman, J. N., Richardson, S. I., & Moore, P. L. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.05.005 · Cited by 9
Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2
Bormann, M., van de Sand, L., Witzke, O., & Krawczyk, A. (2021) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1423-8961 · Cited by 7
“[69] The other licensed mRNA vaccine (mRNA-1273) from Moderna is likewise based on a mRNA formulated with lipid nanoparticles [70].”
BackgroundSevere Acute Respiratory Syndrome Coronavirus‐2
Slev, P. R. (2024) · Wiley eBooks · doi:10.1002/9781683674023.ch54 · Cited by 8
Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging
Zhang, N., Seo, J. W., Robinson, E. R., Rivera‐Rodriguez, A., Wang, J., Guo, Y., Czerwinski, D. K., Kim, H. R., Tumbale, S. K., Raie, M. N., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2504950122 · Cited by 15
“LNP - mRNA technology underlies recent successes in vaccine development ( 23 ) and holds exceptional promise for additional therapeutic strategies in oncology ( 24 ).”
Recent advances in delivering RNA-based therapeutics to mitochondria
Yamada, Y., Ishizuka, S., Arai, M., Maruyama, M., & Harashima, H. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2070427 · Cited by 8
Tapping the immunological imprints to design chimeric SARS-CoV-2 vaccine for elderly population
Biswas, A., Mandal, R. S., Chakraborty, S., & Maiti, G. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1925267 · Cited by 8
“A prime-boost regimen strategy was explored with this vaccine and reported to be well tolerated during the early-stage human trial and elicited dose-dependent immunogenicity [70].”
BackgroundModulation of immune cells with mRNA nanoformulations for cancer immunotherapy
Han, J., & Park, J. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.103014 · Cited by 8
Inflammatory Bowel Disease Triggered by BNT162b2 mRNA Vaccination for SARS-CoV-2
Shimodaira, Y., Watanabe, K., Takahashi, S., Koizumi, S., & Iijima, K. (2021) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab297 · Cited by 8
miRNAs in SARS-CoV-2 Infection: An Update
Azhar, A., Khan, W. H., Alhosaini, K. A., & Kamal, M. A. (2022) · Current Drug Metabolism · doi:10.2174/1389200223666220321102824 · Cited by 8
Murari, T. B., Fonseca, L. M. D. S., Pereira, H. B. D. B., Filho, A. S. N., Saba, H. C., Scorza, F. A., de Almeida, A.-C. G., Maciel, E. L. N., Mendes, J. F. F., Filho, T. M. R., et al. (2022) · Vaccines · doi:10.3390/vaccines10091504 · Cited by 9
“S (Janssen) [10], mRNA BNT162b2 (Pfizer and BioNTech) [11], and mRNA-1273 (Moderna) vaccines [12].”
Natural Immunity Boosters as Therapeutic Interventions in the Era of the COVID-19 Pandemic
Noureen, S., Rehman, K., & Akash, M. S. H. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220110113028 · Cited by 9
Zhao, X., Luo, S., Huang, K., et al. (2021) · Nanoscale · doi:10.1039/d1nr06313h · Cited by 7
Acute myocarditis after receiving first dose of BNT162b2 mRNA vaccine
Wu, B., Mittal, N., ADLER, E. D., & Hong, K. N. (2022) · Journal of Cardiology Cases · doi:10.1016/j.jccase.2021.12.009 · Cited by 8
Fries, L. F., Formica, N. T., Mallory, R. M., Zhou, H., Plested, J. S., Kalkeri, R., Moldovan, I. M., Patel, N., Albert, G. R., Robinson, M., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad163 · Cited by 7
Gillot, C., Bayart, J., Closset, M., Cabo, J., Maloteau, V., Dogné, J., Douxfils, J., & Favresse, J. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-0134 · Cited by 10
Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2/COVID-19 vaccine candidate
Perdiguero, B., Marcos-Villar, L., López‐Bravo, M., Sánchez‐Cordón, P. J., Zamora, C., Valverde, J. R., Sorzano, C. Ó. S., Sin, L., Álvarez, E. A., Ramos, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160065 · Cited by 8
Igari, H., Asano, H., Murata, S., Yoshida, T., Kawasaki, K., Kageyama, T., Ikeda, K., Koshikawa, H., Okuda, Y., Urushihara, M., et al. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.07.010 · Cited by 7
“These SARS-CoV-2 vaccines induced neutralizing humoral and cellular immunity and resulted in reductions of SARS-CoV-2 infections, hospitalizations, and deaths [5,6].”
Real World Estimate of Vaccination Protection in Individuals Hospitalized for COVID-19
Monforte, A. D., Tavelli, A., Benedittis, S. D., Bai, F., Tincati, C., Gazzola, L., Viganò, O., Allegrini, M., Mondatore, D., Tesoro, D., et al. (2022) · Vaccines · doi:10.3390/vaccines10040550 · Cited by 8
“Indeed, at least in the USA and Europe, where notification of cases is closely monitored, the number of cases at country level is inversely proportional to the percent of vaccinated individuals: the lowest is this percentage the highest is the number of new COVID-19 cases and deaths [3,4].”
BackgroundThe European Academy of Neurology N euro COVID ‐19 Task Force: A lesson for the future
Cavallieri, F., Sellner, J., Akhvlediani, T., Bassetti, C. L., Bereczki, D., Fanciulli, A., Filipović, S. R., Guekht, A. B., Helbok, R., Hochmeister, S., et al. (2024) · European Journal of Neurology · doi:10.1111/ene.16321 · Cited by 6
Using nanomaterials to address SARS-CoV-2 variants through development of vaccines and therapeutics
Hangad, M. V., Keshvani, S., Kelpin, N., Walters-Shumka, J. P., Hood, M., Volk, C., Pal, D., & Willerth, S. M. (2022) · Frontiers in Materials · doi:10.3389/fmats.2022.1039247 · Cited by 8
“Two nanoparticle-based vaccines for COVID-19 have been approved for use by Health Canada after their determination as safe and effective: the Pfizer-BioNTech Comirnaty COVID-19 vaccine (BNT162b2 mRNA) (Polack et al., 2020) and Moderna Spikevax COVID-19 vaccine (mRNA-1273 SARS-CoV-2)”
MethodDou, X., Peng, M., Jiang, R., Li, W., & Zhang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1174406 · Cited by 8
Caimi, B., Franzetti, M., Velleca, R., Lai, A., Gatti, A., Rossi, P. L., D'Orso, M. I., Pregliasco, F. E., Balotta, C., & Calicchio, G. (2022) · BMC Geriatrics · doi:10.1186/s12877-022-02884-0 · Cited by 7
COVID-19 Pathogenesis: From Molecular Pathway to Vaccine Administration
Nappi, F., Iervolino, A., & Singh, S. S. A. (2021) · Biomedicines · doi:10.3390/biomedicines9080903 · Cited by 7
“Furthermore, they were equivalent for a median of 2 months when comparing BNT162b2 with that of other viral vaccines [89].”
BackgroundCOVID-19: Variants, Immunity, and Therapeutics for Non-Hospitalized Patients
Lee, C. Y. S., & Suzuki, J. B. (2023) · Biomedicines · doi:10.3390/biomedicines11072055 · Cited by 7
Modeling, Estimation, and Optimal Control of Anti-COVID-19 Multi-dose Vaccine Administration
Scarabaggio, P., Carli, R., Cavone, G., Epicoco, N., & Dotoli, M. (2021) · IEEE International Conference on Automation Science and Engineering (CASE) · doi:10.1109/case49439.2021.9551418 · Cited by 9
“In fact, clinical reports demonstrate 52,4% of efficacy after 22 days for BNT162b2 Pfizer’s vaccine first dose [17].”
BackgroundEmergency Department Utilization by In-hospital Healthcare Workers after COVID-19 Vaccination
Park, M. J., Choi, Y. J., & Choi, S. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e196 · Cited by 7
(2021) · doi:10.1101/2021.06.15.21258928 · Cited by 7
“However, the BNT162b2 and mRNA-1273 vaccines exhibit ~90% effectiveness against infection [3-5], and the Ad26.”
BackgroundEmani, V. R., Pallipuram, V. K., Goswami, K. K., Maddula, K. R., Reddy, R., Nakka, A. S., Panga, S., Reddy, N. K., Reddy, N. K., Nandanoor, D., et al. (2022) · medRxiv · doi:10.1101/2022.06.28.22276926 · Cited by 7
Chen, C., Zhang, Y., Cao, Z., Li, D., Zhu, Y., Jing, H., Li, Y., Li, F., Xu, C., Yang, X., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202406101 · Cited by 15
Cheng, S., Lien, C.-E., Hsieh, S., Cheng, C., Liu, W.-D., Lo, C.-L., Ko, W., Chen, Y., Huang, C., Chang, H., et al. (2022) · Vaccines · doi:10.3390/vaccines11010018 · Cited by 7
Values for a Post-Pandemic Future
Dennis, M., Ishmaev, G., Umbrello, S., & van den Hoven, J. (2022) · Philosophy of engineering and technology · doi:10.1007/978-3-031-08424-9 · Cited by 9
Critical care and pandemic preparedness and response
Thomson, W., Puthucheary, Z., & Wan, Y. I. (2023) · British Journal of Anaesthesia · doi:10.1016/j.bja.2023.07.026 · Cited by 14
Rosa, R. G., Falavigna, M., Manfio, J. L., de Araújo, C. L. P., Cohen, M. M., Barbosa, G. R. G. D. V., de Souza, A. P., Silva, F. K. R., Sganzerla, D., da Silva, M. M. D., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.07.038 · Cited by 8
Pierce, M., Slipke, W., & Biagi, M. J. (2022) · Antibiotics · doi:10.3390/antibiotics11091200 · Cited by 8
Effects of cardiopulmonary bypass on immunoglobulin G antibody titres after SARS-CoV2 vaccination
Hayashi, R., Takami, Y., Fujigaki, H., Amano, K., Sakurai, Y., Akita, K., Yamana, K., Maekawa, A., Saito, K., & Takagi, Y. (2022) · Interactive Cardiovascular and Thoracic Surgery · doi:10.1093/icvts/ivac123 · Cited by 7
Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women
Chayachinda, C., Watananirun, K., Phatihattakorn, C., Anuwutnavin, S., Niyomnaitham, S., Phongsamart, W., Lapphra, K., Wittawatmongkol, O., Rungmaitree, S., Jansarikit, L., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2228670 · Cited by 8
Murwanti, R., Denda‐Nagai, K., Sugiura, D., Mogushi, K., Gendler, S. J., & Irimura, T. (2023) · Cancers · doi:10.3390/cancers15061920 · Cited by 7
“In light of the recent progress regarding the use of mRNA and DNA vaccination technology to stem the COVID-19 pandemic [13,14] and to provide new treatment possibilities for cancer [15], genetic vaccines may soon become an accepted therapeutic modality.”
BackgroundMustafa, Z. U., Maqbool, F., Wahid, M., et al. (2023) · Revista da Sociedade Brasileira de Medicina Tropical · doi:10.1590/0037-8682-0044-2023 · Cited by 7
Friedensohn, L., Zur, M., Timofeyev, M., Burshtein, S., Michael, Y. B., Fink, N., & Glassberg, E. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.07.096 · Cited by 8
“BNT162b2 anti Covid-19 mRNA vaccine (Pfizer, New York, United States (US) and BioNTech, Mainz, Germany) [1] was authorized for emergency use by the Food and Drugs administration [2].”
Sato, T., Nihei, R., Sora, D., Nishio, Y., & Takeuchi, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.967972 · Cited by 7
“From the millions of doses of mRNA COVID-19 vaccines administered, general adverse events that occur in a considerable subset of individuals are mild to moderate reactions at the injection site, fever, fatigue, body aches, and headache (9).”
BackgroundRoier, S., Adamo, R., Rosini, R., Pezzicoli, A., Scarselli, M., Petsch, B., Jasny, E., & Rauch, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1668937 · Cited by 11
Zhang, D., Zhong, J., Xiong, H., Li, Y., Guo, T., Peng, B., Fang, C., Kang, Y., Tan, J., & Ma, Y. (2023) · Vaccines · doi:10.3390/vaccines11030566 · Cited by 6
“Moreover, the vaccine efficacy decreased and antibody levels continued to decline over time [18,19].”
BackgroundGalanis, P., Vraka, I. S., Katsiroumpa, A., Konstantakopoulou, O., Siskou, O. C., Zogaki, E., & Καϊτελίδου, Δ. (2023) · Vaccines · doi:10.3390/vaccines11020269 · Cited by 9
Ye, X., Huang, C., Wei, Y., Li, S. T. H., Yan, V. K. C., Yiu, K., Tse, H., Ma, T., Qin, X. S., Chui, C. S. L., et al. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100630 · Cited by 9
Approved mRNA Vaccines for SARS-CoV-2
Faiman, B. M. (2021) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2021.12.1.1 · Cited by 7
Moghnieh, R., Hajj, C. E., Abdallah, D., Jbeily, N., Bizri, A. R., & Sayegh, M. H. (2022) · Vaccines · doi:10.3390/vaccines10101596 · Cited by 8
“Reactogenicity was similar to that described in previous evaluations of ChAdOx1 nCov-19, Gam-COVID-Vac, and BNT162b2 vaccines and did not differ between heterologous and homologous boosters [39,47,48].”
ResultmRNA Delivery and Storage by Co-Assembling Nanostructures with Designer Oligopeptides
Feng, R., Chang, A. C. Y., Ni, R., Li, C. Y., & Chau, Y. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00397 · Cited by 7
Calzetta, L., Chetta, A. A., Aiello, M., Frizzelli, A., Ora, J., Melis, E., Facciolo, F., Ippoliti, L., Magrini, A., & Rogliani, P. (2023) · Vaccines · doi:10.3390/vaccines11020282 · Cited by 7
“Unexpectedly, after more than two years from the publication of data [18], detailed results regarding the real safety profile of BNT162b2 are not available on the ClinicalTrials.”
BackgroundInfluentialNguyen, T. P., Đỗ, Q., Lan, P. T., Anh, Đ. Đ., Khong, H., Nguyễn, T. V., Hoang, L. V., Dinh, D. V., Pham, H. N., Chu, M. V., et al. (2022) · medRxiv · doi:10.1101/2022.03.22.22272739 · Cited by 7
Tomaiuolo, R., Restelli, U., Faggiano, F. C., Resta, C. D., Albitar‐Nehme, S., Giuliani, F., Derrico, P., Ricciardi, W., Banfi, G., & Ritrovato, M. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0262 · Cited by 7
Diego, J. G.-B., Singh, G., Jangra, S., Handrejk, K., Laporte, M., Chang, L. A., Zahed, S. S. E., Pache, L., Chang, M. W., Warang, P., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1011805 · Cited by 9
“Some nucleotide changes in the viral sequences were detected in some animals, however, they were represented at low frequencies and not consistent across different samples or with the occurrence of breakthrough infections.”
Complications of COVID-19 Vaccines during Pregnancy; a Systematic Review.
SeyedAlinaghi, S., MohsseniPour, M., Saeidi, S., Habibi, P., Dashti, M., Nazarian, N., Noori, T., Pashaei, Z., Bagheri, A. B., Ghasemzadeh, A., et al. (2022) · Archives of Academic Emergency Medicine · doi:10.22037/aaem.v10i1.1622 · Cited by 9
“Although COVID-19 vaccination lowers the chance of acquiring the coronavirus and its mortality with no or minimal major side effects (4, 5), rare”
BackgroundSerological response to a single dose of a SARS-CoV-2 mRNA vaccine
Ramos, A., Cardoso, M. J., Norton, P. M. P. N. S., Sarmento, A., & Guimarães, J. T. (2021) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114223 · Cited by 7
Cappelletti–Montano, B., Demuru, G., Laconi, E., & Musio, M. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1145645 · Cited by 9
“(2), based on the safety data of the pivotal authorization trials of the bnt162b2 and mrna-1273 vaccines (3, 4), a risks-benefits analysis, could (have been) be useful particularly for the younger age groups [cf.”
BackgroundHosseinian, S., Powers, K., Vasudev, M., Palma, A. M., de Assis, R., Jain, A., Horvath, P., Birring, P. S., Andary, R., Au, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.817345 · Cited by 9
“protective efficacy of up to 95% against the targeted virus strain following two doses administered at least 3-4 weeks apart (1, 2).”
BackgroundRefillable nanodrug-capturing systems for extracellular drug delivery and combined cancer therapy
Cao, Z., Hu, L., Zheng, Y., Xiao, Z., Wang, J., Yang, X., & Wang, J. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100053 · Cited by 7
Dennison, L., Williamson, S., Greenwell, K., Handcock, M., Bradbury, K. J., Vennik, J. L., Yardley, L., Little, P. S., & Geraghty, A. W. A. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-055565 · Cited by 14
Deamidation drives molecular aging of the SARS-CoV-2 spike protein receptor-binding motif
Lorenzo, R., Defelipe, L. A., Aliperti, L., Niebling, S., Custódio, T. F., Löw, C., Schwarz, J., Remans, K., Craig, P. O., Otero, L. H., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101175 · Cited by 9
“Beyond S crucial role in restricting viral host infectivity, the protein is the target of potent neutralizing antibodies (10–12) with therapeutic use and the main antigenic component of vaccines (13, 14).”
Streamlined and on-demand preparation of mRNA products on a universal integrated platform
Wei, H., Rong, Z., Liu, L., Sang, Y., Yang, J., & Wang, S. (2023) · Microsystems & Nanoengineering · doi:10.1038/s41378-023-00538-8 · Cited by 8
Upadhyay, A. A., Hoang, T., Pino, M., Boddapati, A. K., Viox, E. G., Lee, M., Corry, J., Strongin, Z., Cowan, D. A., Beagle, E. N., et al. (2021) · bioRxiv · doi:10.1101/2021.10.05.463212 · Cited by 7
Recurrence of Herpetic Keratitis after COVID-19 Vaccination: A Report of Two Cases
Fard, A. M., Desilets, J., & Patel, S. P. (2022) · Case Reports in Ophthalmological Medicine · doi:10.1155/2022/7094893 · Cited by 7
“The COVID-19 vaccines work by generating both adaptive humoral and cellular immune responses in humans, including elevation of anti-spike neutralizing antibody titers, antigen-specific CD4+ and CD8+ T-cell responses, and increased levels of proinflammatory cytokines such as interferon gamma (IFNγ).”
BackgroundInfluentialOn Bayesian Sequential Clinical Trial Designs
Zhou, T., & Ji, Y. (2023) · The New England Journal of Statistics in Data Science · doi:10.51387/23-nejsds24 · Cited by 21
Garg, R., Liu, Q., van Kessel, J., Asavajaru, A., Uhlemann, E.-M. E., Joessel, M., Hamonic, G., Khatooni, Z., Kroeker, A., Lew, J. M., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.05.028 · Cited by 9
Cheng, C. (2022) · Behavioral Sciences · doi:10.3390/bs12070223 · Cited by 7
“Although large-scale, randomized controlled trials have demonstrated the efficacy of COVID-19 vaccines in mitigating infection risk [24], public opinion surveys have revealed mixed attitudes toward COVID-19 vaccination [25,26].”
BackgroundWard, V., Wei, J., Gordon, W., Barnes, E., Dunachie, S., Jeffery, K., Eyre, D., & O-Donnell, A. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-066766 · Cited by 8
Fakonti, G., Kyprianidou, M., Toumbis, G., & Giannakou, K. (2021) · International Journal of Nursing Knowledge · doi:10.1111/2047-3095.12354 · Cited by 7
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.